nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A5—Beclomethasone—psoriasis	0.0749	0.113	CbGbCtD
Nefazodone—CYP2D6—Hydroxyurea—psoriasis	0.0348	0.0527	CbGbCtD
Nefazodone—CYP3A7—Hydrocortisone—psoriasis	0.0319	0.0483	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0319	0.0483	CbGbCtD
Nefazodone—CYP3A7—Cyclosporine—psoriasis	0.0301	0.0456	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0301	0.0456	CbGbCtD
Nefazodone—CYP3A5—Mycophenolate mofetil—psoriasis	0.0298	0.0451	CbGbCtD
Nefazodone—CYP3A4—Calcitriol—psoriasis	0.026	0.0394	CbGbCtD
Nefazodone—CYP3A5—Hydrocortisone—psoriasis	0.0239	0.0362	CbGbCtD
Nefazodone—CYP3A5—Cyclosporine—psoriasis	0.0226	0.0342	CbGbCtD
Nefazodone—CYP2D6—Cholecalciferol—psoriasis	0.0211	0.0319	CbGbCtD
Nefazodone—CYP3A4—Methoxsalen—psoriasis	0.0203	0.0307	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0198	0.03	CbGbCtD
Nefazodone—CYP3A7—Dexamethasone—psoriasis	0.0198	0.03	CbGbCtD
Nefazodone—ABCB1—Mycophenolate mofetil—psoriasis	0.0194	0.0294	CbGbCtD
Nefazodone—ABCB1—Betamethasone—psoriasis	0.0167	0.0252	CbGbCtD
Nefazodone—ABCB1—Prednisolone—psoriasis	0.0164	0.0249	CbGbCtD
Nefazodone—ABCB1—Hydrocortisone—psoriasis	0.0156	0.0236	CbGbCtD
Nefazodone—ABCB1—Prednisone—psoriasis	0.0155	0.0235	CbGbCtD
Nefazodone—CYP3A5—Dexamethasone—psoriasis	0.0149	0.0225	CbGbCtD
Nefazodone—ABCB1—Cyclosporine—psoriasis	0.0147	0.0223	CbGbCtD
Nefazodone—CYP2D6—Cyclosporine—psoriasis	0.0139	0.021	CbGbCtD
Nefazodone—CYP3A4—Cholecalciferol—psoriasis	0.0134	0.0203	CbGbCtD
Nefazodone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0116	0.0176	CbGbCtD
Nefazodone—CYP3A4—Triamcinolone—psoriasis	0.0116	0.0176	CbGbCtD
Nefazodone—CYP3A4—Betamethasone—psoriasis	0.00998	0.0151	CbGbCtD
Nefazodone—CYP3A4—Prednisolone—psoriasis	0.00985	0.0149	CbGbCtD
Nefazodone—ABCB1—Dexamethasone—psoriasis	0.00969	0.0147	CbGbCtD
Nefazodone—CYP3A4—Hydrocortisone—psoriasis	0.00934	0.0141	CbGbCtD
Nefazodone—CYP3A4—Prednisone—psoriasis	0.0093	0.0141	CbGbCtD
Nefazodone—CYP2D6—Dexamethasone—psoriasis	0.00913	0.0138	CbGbCtD
Nefazodone—CYP3A4—Cyclosporine—psoriasis	0.00882	0.0133	CbGbCtD
Nefazodone—ABCB1—Methotrexate—psoriasis	0.00779	0.0118	CbGbCtD
Nefazodone—CYP3A4—Dexamethasone—psoriasis	0.00581	0.00879	CbGbCtD
Nefazodone—Dizziness—Mycophenolic acid—psoriasis	0.000106	0.000329	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—psoriasis	0.000106	0.000329	CcSEcCtD
Nefazodone—Paraesthesia—Prednisolone—psoriasis	0.000106	0.000329	CcSEcCtD
Nefazodone—Tachycardia—Triamcinolone—psoriasis	0.000106	0.000329	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000105	0.000326	CcSEcCtD
Nefazodone—Hyperhidrosis—Triamcinolone—psoriasis	0.000105	0.000325	CcSEcCtD
Nefazodone—Convulsion—Betamethasone—psoriasis	0.000104	0.000324	CcSEcCtD
Nefazodone—Convulsion—Dexamethasone—psoriasis	0.000104	0.000324	CcSEcCtD
Nefazodone—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000104	0.000323	CcSEcCtD
Nefazodone—Insomnia—Hydrocortisone—psoriasis	0.000104	0.000323	CcSEcCtD
Nefazodone—Hypertension—Dexamethasone—psoriasis	0.000104	0.000323	CcSEcCtD
Nefazodone—Hypertension—Betamethasone—psoriasis	0.000104	0.000323	CcSEcCtD
Nefazodone—Paraesthesia—Hydrocortisone—psoriasis	0.000103	0.000321	CcSEcCtD
Nefazodone—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000103	0.000321	CcSEcCtD
Nefazodone—Urticaria—Cyclosporine—psoriasis	0.000103	0.00032	CcSEcCtD
Nefazodone—Myalgia—Dexamethasone—psoriasis	0.000103	0.000319	CcSEcCtD
Nefazodone—Myalgia—Betamethasone—psoriasis	0.000103	0.000319	CcSEcCtD
Nefazodone—Abdominal pain—Cyclosporine—psoriasis	0.000102	0.000318	CcSEcCtD
Nefazodone—Body temperature increased—Cyclosporine—psoriasis	0.000102	0.000318	CcSEcCtD
Nefazodone—Anxiety—Dexamethasone—psoriasis	0.000102	0.000318	CcSEcCtD
Nefazodone—Anxiety—Betamethasone—psoriasis	0.000102	0.000318	CcSEcCtD
Nefazodone—Vomiting—Mycophenolic acid—psoriasis	0.000102	0.000316	CcSEcCtD
Nefazodone—Discomfort—Dexamethasone—psoriasis	0.000101	0.000315	CcSEcCtD
Nefazodone—Discomfort—Betamethasone—psoriasis	0.000101	0.000315	CcSEcCtD
Nefazodone—Dyspepsia—Hydrocortisone—psoriasis	0.000101	0.000315	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—psoriasis	0.000101	0.000314	CcSEcCtD
Nefazodone—Rash—Mycophenolic acid—psoriasis	0.000101	0.000314	CcSEcCtD
Nefazodone—Dermatitis—Mycophenolic acid—psoriasis	0.000101	0.000313	CcSEcCtD
Nefazodone—Pain—Prednisolone—psoriasis	0.000101	0.000313	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—psoriasis	0.000101	0.000313	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—psoriasis	0.000101	0.000313	CcSEcCtD
Nefazodone—Urticaria—Mycophenolate mofetil—psoriasis	0.0001	0.000312	CcSEcCtD
Nefazodone—Headache—Mycophenolic acid—psoriasis	0.0001	0.000312	CcSEcCtD
Nefazodone—Decreased appetite—Hydrocortisone—psoriasis	0.0001	0.000311	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—psoriasis	0.0001	0.000311	CcSEcCtD
Nefazodone—Abdominal pain—Mycophenolate mofetil—psoriasis	9.99e-05	0.00031	CcSEcCtD
Nefazodone—Body temperature increased—Mycophenolate mofetil—psoriasis	9.99e-05	0.00031	CcSEcCtD
Nefazodone—Vision blurred—Prednisone—psoriasis	9.9e-05	0.000307	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.88e-05	0.000307	CcSEcCtD
Nefazodone—Pain—Hydrocortisone—psoriasis	9.85e-05	0.000306	CcSEcCtD
Nefazodone—Anaphylactic shock—Dexamethasone—psoriasis	9.84e-05	0.000305	CcSEcCtD
Nefazodone—Oedema—Dexamethasone—psoriasis	9.84e-05	0.000305	CcSEcCtD
Nefazodone—Anaphylactic shock—Betamethasone—psoriasis	9.84e-05	0.000305	CcSEcCtD
Nefazodone—Oedema—Betamethasone—psoriasis	9.84e-05	0.000305	CcSEcCtD
Nefazodone—Insomnia—Triamcinolone—psoriasis	9.81e-05	0.000304	CcSEcCtD
Nefazodone—Infection—Betamethasone—psoriasis	9.78e-05	0.000303	CcSEcCtD
Nefazodone—Infection—Dexamethasone—psoriasis	9.78e-05	0.000303	CcSEcCtD
Nefazodone—Ill-defined disorder—Prednisone—psoriasis	9.74e-05	0.000302	CcSEcCtD
Nefazodone—Paraesthesia—Triamcinolone—psoriasis	9.74e-05	0.000302	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisolone—psoriasis	9.72e-05	0.000302	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—psoriasis	9.71e-05	0.000302	CcSEcCtD
Nefazodone—Anaemia—Prednisone—psoriasis	9.71e-05	0.000301	CcSEcCtD
Nefazodone—Shock—Dexamethasone—psoriasis	9.68e-05	0.000301	CcSEcCtD
Nefazodone—Shock—Betamethasone—psoriasis	9.68e-05	0.000301	CcSEcCtD
Nefazodone—Dyspnoea—Triamcinolone—psoriasis	9.67e-05	0.0003	CcSEcCtD
Nefazodone—Agitation—Prednisone—psoriasis	9.65e-05	0.0003	CcSEcCtD
Nefazodone—Thrombocytopenia—Betamethasone—psoriasis	9.63e-05	0.000299	CcSEcCtD
Nefazodone—Thrombocytopenia—Dexamethasone—psoriasis	9.63e-05	0.000299	CcSEcCtD
Nefazodone—Tachycardia—Betamethasone—psoriasis	9.6e-05	0.000298	CcSEcCtD
Nefazodone—Tachycardia—Dexamethasone—psoriasis	9.6e-05	0.000298	CcSEcCtD
Nefazodone—Angioedema—Prednisone—psoriasis	9.59e-05	0.000298	CcSEcCtD
Nefazodone—Hypersensitivity—Cyclosporine—psoriasis	9.55e-05	0.000296	CcSEcCtD
Nefazodone—Dyspepsia—Triamcinolone—psoriasis	9.55e-05	0.000296	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—psoriasis	9.53e-05	0.000296	CcSEcCtD
Nefazodone—Nausea—Mycophenolic acid—psoriasis	9.52e-05	0.000295	CcSEcCtD
Nefazodone—Hyperhidrosis—Dexamethasone—psoriasis	9.51e-05	0.000295	CcSEcCtD
Nefazodone—Hyperhidrosis—Betamethasone—psoriasis	9.51e-05	0.000295	CcSEcCtD
Nefazodone—Feeling abnormal—Hydrocortisone—psoriasis	9.49e-05	0.000295	CcSEcCtD
Nefazodone—Malaise—Prednisone—psoriasis	9.47e-05	0.000294	CcSEcCtD
Nefazodone—Vertigo—Prednisone—psoriasis	9.43e-05	0.000293	CcSEcCtD
Nefazodone—Gastrointestinal pain—Hydrocortisone—psoriasis	9.42e-05	0.000292	CcSEcCtD
Nefazodone—Syncope—Prednisone—psoriasis	9.42e-05	0.000292	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—psoriasis	9.4e-05	0.000292	CcSEcCtD
Nefazodone—Anorexia—Betamethasone—psoriasis	9.38e-05	0.000291	CcSEcCtD
Nefazodone—Anorexia—Dexamethasone—psoriasis	9.38e-05	0.000291	CcSEcCtD
Nefazodone—Urticaria—Prednisolone—psoriasis	9.37e-05	0.000291	CcSEcCtD
Nefazodone—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.31e-05	0.000289	CcSEcCtD
Nefazodone—Asthenia—Cyclosporine—psoriasis	9.3e-05	0.000289	CcSEcCtD
Nefazodone—Pain—Triamcinolone—psoriasis	9.27e-05	0.000288	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisone—psoriasis	9.23e-05	0.000286	CcSEcCtD
Nefazodone—Hypotension—Betamethasone—psoriasis	9.2e-05	0.000285	CcSEcCtD
Nefazodone—Hypotension—Dexamethasone—psoriasis	9.2e-05	0.000285	CcSEcCtD
Nefazodone—Pruritus—Cyclosporine—psoriasis	9.17e-05	0.000285	CcSEcCtD
Nefazodone—Urticaria—Hydrocortisone—psoriasis	9.15e-05	0.000284	CcSEcCtD
Nefazodone—Abdominal pain—Hydrocortisone—psoriasis	9.11e-05	0.000283	CcSEcCtD
Nefazodone—Body temperature increased—Hydrocortisone—psoriasis	9.11e-05	0.000283	CcSEcCtD
Nefazodone—Convulsion—Prednisone—psoriasis	9.1e-05	0.000282	CcSEcCtD
Nefazodone—Asthenia—Mycophenolate mofetil—psoriasis	9.07e-05	0.000282	CcSEcCtD
Nefazodone—Hypertension—Prednisone—psoriasis	9.07e-05	0.000281	CcSEcCtD
Nefazodone—Chills—Methotrexate—psoriasis	9.05e-05	0.000281	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.97e-05	0.000278	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Betamethasone—psoriasis	8.97e-05	0.000278	CcSEcCtD
Nefazodone—Pruritus—Mycophenolate mofetil—psoriasis	8.94e-05	0.000278	CcSEcCtD
Nefazodone—Arthralgia—Prednisone—psoriasis	8.94e-05	0.000277	CcSEcCtD
Nefazodone—Myalgia—Prednisone—psoriasis	8.94e-05	0.000277	CcSEcCtD
Nefazodone—Feeling abnormal—Triamcinolone—psoriasis	8.94e-05	0.000277	CcSEcCtD
Nefazodone—Anxiety—Prednisone—psoriasis	8.91e-05	0.000277	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—psoriasis	8.91e-05	0.000277	CcSEcCtD
Nefazodone—Insomnia—Dexamethasone—psoriasis	8.9e-05	0.000276	CcSEcCtD
Nefazodone—Insomnia—Betamethasone—psoriasis	8.9e-05	0.000276	CcSEcCtD
Nefazodone—Diarrhoea—Cyclosporine—psoriasis	8.87e-05	0.000275	CcSEcCtD
Nefazodone—Paraesthesia—Dexamethasone—psoriasis	8.84e-05	0.000274	CcSEcCtD
Nefazodone—Paraesthesia—Betamethasone—psoriasis	8.84e-05	0.000274	CcSEcCtD
Nefazodone—Discomfort—Prednisone—psoriasis	8.83e-05	0.000274	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisolone—psoriasis	8.69e-05	0.00027	CcSEcCtD
Nefazodone—Dyspepsia—Betamethasone—psoriasis	8.66e-05	0.000269	CcSEcCtD
Nefazodone—Dyspepsia—Dexamethasone—psoriasis	8.66e-05	0.000269	CcSEcCtD
Nefazodone—Diarrhoea—Mycophenolate mofetil—psoriasis	8.65e-05	0.000268	CcSEcCtD
Nefazodone—Urticaria—Triamcinolone—psoriasis	8.62e-05	0.000267	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—psoriasis	8.59e-05	0.000267	CcSEcCtD
Nefazodone—Body temperature increased—Triamcinolone—psoriasis	8.57e-05	0.000266	CcSEcCtD
Nefazodone—Dizziness—Cyclosporine—psoriasis	8.57e-05	0.000266	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisone—psoriasis	8.57e-05	0.000266	CcSEcCtD
Nefazodone—Oedema—Prednisone—psoriasis	8.57e-05	0.000266	CcSEcCtD
Nefazodone—Decreased appetite—Dexamethasone—psoriasis	8.55e-05	0.000266	CcSEcCtD
Nefazodone—Decreased appetite—Betamethasone—psoriasis	8.55e-05	0.000266	CcSEcCtD
Nefazodone—Infection—Prednisone—psoriasis	8.51e-05	0.000264	CcSEcCtD
Nefazodone—Back pain—Methotrexate—psoriasis	8.49e-05	0.000263	CcSEcCtD
Nefazodone—Hypersensitivity—Hydrocortisone—psoriasis	8.49e-05	0.000263	CcSEcCtD
Nefazodone—Shock—Prednisone—psoriasis	8.43e-05	0.000262	CcSEcCtD
Nefazodone—Pain—Dexamethasone—psoriasis	8.41e-05	0.000261	CcSEcCtD
Nefazodone—Pain—Betamethasone—psoriasis	8.41e-05	0.000261	CcSEcCtD
Nefazodone—Tachycardia—Prednisone—psoriasis	8.36e-05	0.00026	CcSEcCtD
Nefazodone—Dizziness—Mycophenolate mofetil—psoriasis	8.36e-05	0.000259	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisone—psoriasis	8.28e-05	0.000257	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—psoriasis	8.27e-05	0.000257	CcSEcCtD
Nefazodone—Asthenia—Hydrocortisone—psoriasis	8.26e-05	0.000257	CcSEcCtD
Nefazodone—Vomiting—Cyclosporine—psoriasis	8.24e-05	0.000256	CcSEcCtD
Nefazodone—Rash—Cyclosporine—psoriasis	8.17e-05	0.000254	CcSEcCtD
Nefazodone—Anorexia—Prednisone—psoriasis	8.17e-05	0.000254	CcSEcCtD
Nefazodone—Dermatitis—Cyclosporine—psoriasis	8.16e-05	0.000253	CcSEcCtD
Nefazodone—Pruritus—Hydrocortisone—psoriasis	8.15e-05	0.000253	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—psoriasis	8.14e-05	0.000253	CcSEcCtD
Nefazodone—Headache—Cyclosporine—psoriasis	8.12e-05	0.000252	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—psoriasis	8.11e-05	0.000252	CcSEcCtD
Nefazodone—Feeling abnormal—Dexamethasone—psoriasis	8.11e-05	0.000252	CcSEcCtD
Nefazodone—Feeling abnormal—Betamethasone—psoriasis	8.11e-05	0.000252	CcSEcCtD
Nefazodone—Gastrointestinal pain—Dexamethasone—psoriasis	8.05e-05	0.00025	CcSEcCtD
Nefazodone—Gastrointestinal pain—Betamethasone—psoriasis	8.05e-05	0.00025	CcSEcCtD
Nefazodone—Vomiting—Mycophenolate mofetil—psoriasis	8.04e-05	0.00025	CcSEcCtD
Nefazodone—Hypersensitivity—Triamcinolone—psoriasis	7.99e-05	0.000248	CcSEcCtD
Nefazodone—Rash—Mycophenolate mofetil—psoriasis	7.97e-05	0.000247	CcSEcCtD
Nefazodone—Dermatitis—Mycophenolate mofetil—psoriasis	7.96e-05	0.000247	CcSEcCtD
Nefazodone—Headache—Mycophenolate mofetil—psoriasis	7.92e-05	0.000246	CcSEcCtD
Nefazodone—Malaise—Methotrexate—psoriasis	7.91e-05	0.000246	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—psoriasis	7.88e-05	0.000245	CcSEcCtD
Nefazodone—Diarrhoea—Hydrocortisone—psoriasis	7.88e-05	0.000245	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—psoriasis	7.86e-05	0.000244	CcSEcCtD
Nefazodone—Urticaria—Dexamethasone—psoriasis	7.82e-05	0.000243	CcSEcCtD
Nefazodone—Urticaria—Betamethasone—psoriasis	7.82e-05	0.000243	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Prednisone—psoriasis	7.81e-05	0.000242	CcSEcCtD
Nefazodone—Dizziness—Prednisolone—psoriasis	7.8e-05	0.000242	CcSEcCtD
Nefazodone—Asthenia—Triamcinolone—psoriasis	7.78e-05	0.000242	CcSEcCtD
Nefazodone—Body temperature increased—Dexamethasone—psoriasis	7.78e-05	0.000241	CcSEcCtD
Nefazodone—Abdominal pain—Dexamethasone—psoriasis	7.78e-05	0.000241	CcSEcCtD
Nefazodone—Body temperature increased—Betamethasone—psoriasis	7.78e-05	0.000241	CcSEcCtD
Nefazodone—Abdominal pain—Betamethasone—psoriasis	7.78e-05	0.000241	CcSEcCtD
Nefazodone—Insomnia—Prednisone—psoriasis	7.75e-05	0.000241	CcSEcCtD
Nefazodone—Nausea—Cyclosporine—psoriasis	7.7e-05	0.000239	CcSEcCtD
Nefazodone—Paraesthesia—Prednisone—psoriasis	7.7e-05	0.000239	CcSEcCtD
Nefazodone—Pruritus—Triamcinolone—psoriasis	7.67e-05	0.000238	CcSEcCtD
Nefazodone—Cough—Methotrexate—psoriasis	7.66e-05	0.000238	CcSEcCtD
Nefazodone—Dizziness—Hydrocortisone—psoriasis	7.62e-05	0.000236	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—psoriasis	7.6e-05	0.000236	CcSEcCtD
Nefazodone—Dyspepsia—Prednisone—psoriasis	7.54e-05	0.000234	CcSEcCtD
Nefazodone—Nausea—Mycophenolate mofetil—psoriasis	7.51e-05	0.000233	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—psoriasis	7.47e-05	0.000232	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—psoriasis	7.47e-05	0.000232	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—psoriasis	7.47e-05	0.000232	CcSEcCtD
Nefazodone—Decreased appetite—Prednisone—psoriasis	7.45e-05	0.000231	CcSEcCtD
Nefazodone—Rash—Prednisolone—psoriasis	7.44e-05	0.000231	CcSEcCtD
Nefazodone—Dermatitis—Prednisolone—psoriasis	7.43e-05	0.000231	CcSEcCtD
Nefazodone—Headache—Prednisolone—psoriasis	7.39e-05	0.000229	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—psoriasis	7.38e-05	0.000229	CcSEcCtD
Nefazodone—Constipation—Prednisone—psoriasis	7.33e-05	0.000227	CcSEcCtD
Nefazodone—Vomiting—Hydrocortisone—psoriasis	7.32e-05	0.000227	CcSEcCtD
Nefazodone—Rash—Hydrocortisone—psoriasis	7.26e-05	0.000225	CcSEcCtD
Nefazodone—Dermatitis—Hydrocortisone—psoriasis	7.26e-05	0.000225	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—psoriasis	7.22e-05	0.000224	CcSEcCtD
Nefazodone—Headache—Hydrocortisone—psoriasis	7.22e-05	0.000224	CcSEcCtD
Nefazodone—Dizziness—Triamcinolone—psoriasis	7.17e-05	0.000223	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—psoriasis	7.16e-05	0.000222	CcSEcCtD
Nefazodone—Infection—Methotrexate—psoriasis	7.12e-05	0.000221	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisone—psoriasis	7.06e-05	0.000219	CcSEcCtD
Nefazodone—Asthenia—Dexamethasone—psoriasis	7.06e-05	0.000219	CcSEcCtD
Nefazodone—Asthenia—Betamethasone—psoriasis	7.06e-05	0.000219	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—psoriasis	7.01e-05	0.000218	CcSEcCtD
Nefazodone—Gastrointestinal pain—Prednisone—psoriasis	7.01e-05	0.000218	CcSEcCtD
Nefazodone—Nausea—Prednisolone—psoriasis	7e-05	0.000217	CcSEcCtD
Nefazodone—Pruritus—Dexamethasone—psoriasis	6.96e-05	0.000216	CcSEcCtD
Nefazodone—Pruritus—Betamethasone—psoriasis	6.96e-05	0.000216	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—psoriasis	6.92e-05	0.000215	CcSEcCtD
Nefazodone—Vomiting—Triamcinolone—psoriasis	6.9e-05	0.000214	CcSEcCtD
Nefazodone—Nausea—Hydrocortisone—psoriasis	6.84e-05	0.000212	CcSEcCtD
Nefazodone—Rash—Triamcinolone—psoriasis	6.84e-05	0.000212	CcSEcCtD
Nefazodone—Dermatitis—Triamcinolone—psoriasis	6.83e-05	0.000212	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—psoriasis	6.83e-05	0.000212	CcSEcCtD
Nefazodone—Urticaria—Prednisone—psoriasis	6.81e-05	0.000211	CcSEcCtD
Nefazodone—Headache—Triamcinolone—psoriasis	6.79e-05	0.000211	CcSEcCtD
Nefazodone—Abdominal pain—Prednisone—psoriasis	6.77e-05	0.00021	CcSEcCtD
Nefazodone—Body temperature increased—Prednisone—psoriasis	6.77e-05	0.00021	CcSEcCtD
Nefazodone—Diarrhoea—Dexamethasone—psoriasis	6.73e-05	0.000209	CcSEcCtD
Nefazodone—Diarrhoea—Betamethasone—psoriasis	6.73e-05	0.000209	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—psoriasis	6.69e-05	0.000208	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—psoriasis	6.53e-05	0.000203	CcSEcCtD
Nefazodone—Dizziness—Betamethasone—psoriasis	6.51e-05	0.000202	CcSEcCtD
Nefazodone—Dizziness—Dexamethasone—psoriasis	6.51e-05	0.000202	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—psoriasis	6.48e-05	0.000201	CcSEcCtD
Nefazodone—Nausea—Triamcinolone—psoriasis	6.44e-05	0.0002	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—psoriasis	6.43e-05	0.0002	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—psoriasis	6.39e-05	0.000198	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—psoriasis	6.37e-05	0.000198	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisone—psoriasis	6.31e-05	0.000196	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—psoriasis	6.3e-05	0.000196	CcSEcCtD
Nefazodone—Vomiting—Dexamethasone—psoriasis	6.26e-05	0.000194	CcSEcCtD
Nefazodone—Vomiting—Betamethasone—psoriasis	6.26e-05	0.000194	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—psoriasis	6.23e-05	0.000193	CcSEcCtD
Nefazodone—Rash—Dexamethasone—psoriasis	6.2e-05	0.000193	CcSEcCtD
Nefazodone—Rash—Betamethasone—psoriasis	6.2e-05	0.000193	CcSEcCtD
Nefazodone—Dermatitis—Dexamethasone—psoriasis	6.2e-05	0.000192	CcSEcCtD
Nefazodone—Dermatitis—Betamethasone—psoriasis	6.2e-05	0.000192	CcSEcCtD
Nefazodone—Headache—Dexamethasone—psoriasis	6.16e-05	0.000191	CcSEcCtD
Nefazodone—Headache—Betamethasone—psoriasis	6.16e-05	0.000191	CcSEcCtD
Nefazodone—Asthenia—Prednisone—psoriasis	6.15e-05	0.000191	CcSEcCtD
Nefazodone—Pain—Methotrexate—psoriasis	6.12e-05	0.00019	CcSEcCtD
Nefazodone—Pruritus—Prednisone—psoriasis	6.06e-05	0.000188	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—psoriasis	5.9e-05	0.000183	CcSEcCtD
Nefazodone—Diarrhoea—Prednisone—psoriasis	5.86e-05	0.000182	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—psoriasis	5.86e-05	0.000182	CcSEcCtD
Nefazodone—Nausea—Betamethasone—psoriasis	5.85e-05	0.000181	CcSEcCtD
Nefazodone—Nausea—Dexamethasone—psoriasis	5.85e-05	0.000181	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—psoriasis	5.69e-05	0.000177	CcSEcCtD
Nefazodone—Dizziness—Prednisone—psoriasis	5.67e-05	0.000176	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—psoriasis	5.66e-05	0.000176	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—psoriasis	5.66e-05	0.000176	CcSEcCtD
Nefazodone—Vomiting—Prednisone—psoriasis	5.45e-05	0.000169	CcSEcCtD
Nefazodone—Rash—Prednisone—psoriasis	5.4e-05	0.000168	CcSEcCtD
Nefazodone—Dermatitis—Prednisone—psoriasis	5.4e-05	0.000168	CcSEcCtD
Nefazodone—Headache—Prednisone—psoriasis	5.37e-05	0.000167	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—psoriasis	5.28e-05	0.000164	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—psoriasis	5.14e-05	0.000159	CcSEcCtD
Nefazodone—Nausea—Prednisone—psoriasis	5.09e-05	0.000158	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—psoriasis	5.07e-05	0.000157	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—psoriasis	4.9e-05	0.000152	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—psoriasis	4.74e-05	0.000147	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—psoriasis	4.55e-05	0.000141	CcSEcCtD
Nefazodone—Rash—Methotrexate—psoriasis	4.52e-05	0.00014	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—psoriasis	4.51e-05	0.00014	CcSEcCtD
Nefazodone—Headache—Methotrexate—psoriasis	4.49e-05	0.000139	CcSEcCtD
Nefazodone—Nausea—Methotrexate—psoriasis	4.25e-05	0.000132	CcSEcCtD
Nefazodone—HTR1A—Signaling by GPCR—HCAR2—psoriasis	4.22e-05	0.00248	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HCAR2—psoriasis	4.2e-05	0.00247	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—IL10—psoriasis	4.17e-05	0.00246	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—CCL20—psoriasis	4.06e-05	0.00239	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	4.06e-05	0.00239	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HCAR2—psoriasis	4.02e-05	0.00236	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—HCAR2—psoriasis	4.01e-05	0.00236	CbGpPWpGaD
Nefazodone—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	4.01e-05	0.00236	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.99e-05	0.00235	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HCAR2—psoriasis	3.93e-05	0.00231	CbGpPWpGaD
Nefazodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.92e-05	0.00231	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.79e-05	0.00223	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—CCL20—psoriasis	3.69e-05	0.00217	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HCAR2—psoriasis	3.65e-05	0.00215	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.64e-05	0.00215	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HCAR2—psoriasis	3.64e-05	0.00215	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	3.63e-05	0.00214	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—CCL20—psoriasis	3.61e-05	0.00213	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HCAR2—psoriasis	3.57e-05	0.0021	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	3.53e-05	0.00208	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	3.47e-05	0.00204	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.39e-05	0.002	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—CCL20—psoriasis	3.35e-05	0.00198	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HCAR2—psoriasis	3.31e-05	0.00195	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	3.22e-05	0.0019	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NDUFA5—psoriasis	3.16e-05	0.00186	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.08e-05	0.00181	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	3.07e-05	0.00181	CbGpPWpGaD
Nefazodone—ADRA1B—AMPK Signaling—TP53—psoriasis	2.97e-05	0.00175	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—JUN—psoriasis	2.88e-05	0.00169	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—ITGAL—psoriasis	2.77e-05	0.00163	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP2S1—psoriasis	2.68e-05	0.00158	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—IFNG—psoriasis	2.66e-05	0.00157	CbGpPWpGaD
Nefazodone—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.66e-05	0.00156	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.64e-05	0.00156	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	2.64e-05	0.00155	CbGpPWpGaD
Nefazodone—ADRA1A—AMPK Signaling—TP53—psoriasis	2.63e-05	0.00155	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HCAR2—psoriasis	2.49e-05	0.00147	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NDUFA5—psoriasis	2.49e-05	0.00147	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HCAR2—psoriasis	2.48e-05	0.00146	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.47e-05	0.00146	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—JUN—psoriasis	2.46e-05	0.00145	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CCL20—psoriasis	2.41e-05	0.00142	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CCL20—psoriasis	2.4e-05	0.00141	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HCAR2—psoriasis	2.37e-05	0.0014	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.36e-05	0.00139	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.34e-05	0.00138	CbGpPWpGaD
Nefazodone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.32e-05	0.00137	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CCL20—psoriasis	2.3e-05	0.00135	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.28e-05	0.00134	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NDUFA5—psoriasis	2.28e-05	0.00134	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.24e-05	0.00132	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CCL20—psoriasis	2.19e-05	0.00129	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CCL20—psoriasis	2.18e-05	0.00128	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TAGAP—psoriasis	2.16e-05	0.00127	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HCAR2—psoriasis	2.15e-05	0.00127	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TAGAP—psoriasis	2.15e-05	0.00127	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.15e-05	0.00126	CbGpPWpGaD
Nefazodone—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	2.13e-05	0.00125	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	2.12e-05	0.00125	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP2S1—psoriasis	2.12e-05	0.00125	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HCAR2—psoriasis	2.11e-05	0.00124	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CCL20—psoriasis	2.09e-05	0.00123	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CCL20—psoriasis	2.08e-05	0.00123	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TAGAP—psoriasis	2.06e-05	0.00121	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.04e-05	0.0012	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CCL20—psoriasis	2.04e-05	0.0012	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.04e-05	0.0012	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.03e-05	0.00119	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.01e-05	0.00118	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	1.99e-05	0.00117	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HCAR2—psoriasis	1.96e-05	0.00115	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP2S1—psoriasis	1.94e-05	0.00114	CbGpPWpGaD
Nefazodone—HTR1A—G alpha (i) signalling events—CXCL8—psoriasis	1.9e-05	0.00112	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—TP53—psoriasis	1.9e-05	0.00112	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CCL20—psoriasis	1.9e-05	0.00112	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CCL20—psoriasis	1.89e-05	0.00111	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TAGAP—psoriasis	1.87e-05	0.0011	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.85e-05	0.00109	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CCL20—psoriasis	1.85e-05	0.00109	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—TNF—psoriasis	1.84e-05	0.00108	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TAGAP—psoriasis	1.83e-05	0.00108	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—IL6—psoriasis	1.74e-05	0.00102	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—TNF—psoriasis	1.72e-05	0.00101	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NDUFA5—psoriasis	1.72e-05	0.00101	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CCL20—psoriasis	1.72e-05	0.00101	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.71e-05	0.00101	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TAGAP—psoriasis	1.7e-05	0.001	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NDUFA5—psoriasis	1.62e-05	0.000956	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.6e-05	0.000942	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	1.59e-05	0.000936	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.53e-05	0.000899	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.51e-05	0.000891	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.51e-05	0.000887	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—CXCL8—psoriasis	1.5e-05	0.000881	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—IL6—psoriasis	1.48e-05	0.000874	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP2S1—psoriasis	1.46e-05	0.000862	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.44e-05	0.000849	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.38e-05	0.000813	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CARM1—psoriasis	1.31e-05	0.000772	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.31e-05	0.00077	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCL20—psoriasis	1.29e-05	0.000762	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCL20—psoriasis	1.29e-05	0.000758	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	1.28e-05	0.000755	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.28e-05	0.000754	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.28e-05	0.000752	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL20—psoriasis	1.23e-05	0.000726	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.19e-05	0.0007	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—CXCL8—psoriasis	1.15e-05	0.000679	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—CXCL8—psoriasis	1.15e-05	0.000675	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.14e-05	0.000673	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—NOS2—psoriasis	1.14e-05	0.000669	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.14e-05	0.000669	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL20—psoriasis	1.12e-05	0.000658	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—CXCL8—psoriasis	1.1e-05	0.000646	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL20—psoriasis	1.09e-05	0.000644	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.09e-05	0.000644	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.09e-05	0.000644	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.06e-05	0.000625	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CARM1—psoriasis	1.03e-05	0.000609	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL20—psoriasis	1.02e-05	0.000599	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—CXCL8—psoriasis	9.96e-06	0.000586	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	9.92e-06	0.000584	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.92e-06	0.000584	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—CXCL8—psoriasis	9.75e-06	0.000574	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	9.71e-06	0.000572	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CARM1—psoriasis	9.48e-06	0.000558	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	9.06e-06	0.000533	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2S1—psoriasis	9.02e-06	0.000531	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.5e-06	0.000501	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CAT—psoriasis	8.06e-06	0.000475	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.49e-06	0.000441	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CARM1—psoriasis	7.15e-06	0.000421	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SOCS1—psoriasis	7.13e-06	0.00042	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SOCS1—psoriasis	7.09e-06	0.000417	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—TYK2—psoriasis	6.79e-06	0.0004	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SOCS1—psoriasis	6.79e-06	0.0004	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TYK2—psoriasis	6.76e-06	0.000398	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CARM1—psoriasis	6.74e-06	0.000397	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—VEGFA—psoriasis	6.58e-06	0.000387	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	6.51e-06	0.000384	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	6.48e-06	0.000382	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TYK2—psoriasis	6.47e-06	0.000381	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CAT—psoriasis	6.36e-06	0.000375	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—APOE—psoriasis	6.27e-06	0.000369	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	6.2e-06	0.000365	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SOCS1—psoriasis	6.16e-06	0.000362	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SOCS1—psoriasis	6.03e-06	0.000355	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CXCL8—psoriasis	5.92e-06	0.000348	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CXCL8—psoriasis	5.88e-06	0.000346	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TYK2—psoriasis	5.87e-06	0.000346	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CAT—psoriasis	5.83e-06	0.000343	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TYK2—psoriasis	5.75e-06	0.000338	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	5.63e-06	0.000332	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	5.63e-06	0.000331	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SOCS1—psoriasis	5.6e-06	0.00033	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	5.51e-06	0.000324	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PPARG—psoriasis	5.46e-06	0.000321	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TYK2—psoriasis	5.34e-06	0.000314	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—LEP—psoriasis	5.26e-06	0.00031	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—APOE—psoriasis	5.26e-06	0.00031	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—APOE—psoriasis	5.23e-06	0.000308	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—LEP—psoriasis	5.23e-06	0.000308	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	5.12e-06	0.000301	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CXCL8—psoriasis	5.11e-06	0.000301	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—LEP—psoriasis	5.01e-06	0.000295	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APOE—psoriasis	5.01e-06	0.000295	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	5e-06	0.000295	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—psoriasis	4.97e-06	0.000293	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOE—psoriasis	4.94e-06	0.000291	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NFKBIA—psoriasis	4.9e-06	0.000289	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NFKBIA—psoriasis	4.87e-06	0.000287	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	4.67e-06	0.000275	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	4.65e-06	0.000274	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—psoriasis	4.54e-06	0.000267	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—LEP—psoriasis	4.54e-06	0.000267	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—psoriasis	4.53e-06	0.000267	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LEP—psoriasis	4.45e-06	0.000262	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—psoriasis	4.45e-06	0.000262	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CARM1—psoriasis	4.41e-06	0.000259	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAT—psoriasis	4.4e-06	0.000259	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—psoriasis	4.3e-06	0.000253	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFKBIA—psoriasis	4.23e-06	0.000249	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAT—psoriasis	4.14e-06	0.000244	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	4.14e-06	0.000244	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—psoriasis	4.13e-06	0.000243	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—psoriasis	4.13e-06	0.000243	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TYK2—psoriasis	4.01e-06	0.000236	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TYK2—psoriasis	3.99e-06	0.000235	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—psoriasis	3.95e-06	0.000232	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	3.85e-06	0.000227	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TYK2—psoriasis	3.82e-06	0.000225	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—psoriasis	3.49e-06	0.000206	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—psoriasis	3.48e-06	0.000205	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TYK2—psoriasis	3.47e-06	0.000204	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—psoriasis	3.42e-06	0.000201	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TYK2—psoriasis	3.39e-06	0.0002	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—psoriasis	3.33e-06	0.000196	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—psoriasis	3.32e-06	0.000196	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—psoriasis	3.31e-06	0.000195	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JUN—psoriasis	3.25e-06	0.000191	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JUN—psoriasis	3.23e-06	0.00019	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—psoriasis	3.22e-06	0.00019	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—psoriasis	3.16e-06	0.000186	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TYK2—psoriasis	3.15e-06	0.000186	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NFKB1—psoriasis	3.13e-06	0.000184	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NFKB1—psoriasis	3.11e-06	0.000183	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JUN—psoriasis	3.09e-06	0.000182	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—psoriasis	3.02e-06	0.000178	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NFKB1—psoriasis	2.98e-06	0.000175	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—psoriasis	2.98e-06	0.000175	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—psoriasis	2.96e-06	0.000174	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—psoriasis	2.87e-06	0.000169	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—psoriasis	2.84e-06	0.000167	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—psoriasis	2.82e-06	0.000166	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—psoriasis	2.81e-06	0.000165	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—psoriasis	2.81e-06	0.000165	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JUN—psoriasis	2.81e-06	0.000165	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—psoriasis	2.81e-06	0.000165	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—psoriasis	2.8e-06	0.000165	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JUN—psoriasis	2.75e-06	0.000162	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—psoriasis	2.75e-06	0.000162	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAT—psoriasis	2.71e-06	0.00016	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—psoriasis	2.7e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFKB1—psoriasis	2.7e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—psoriasis	2.68e-06	0.000158	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKB1—psoriasis	2.65e-06	0.000156	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—psoriasis	2.61e-06	0.000154	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JUN—psoriasis	2.55e-06	0.00015	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKB1—psoriasis	2.46e-06	0.000145	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—psoriasis	2.45e-06	0.000144	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—psoriasis	2.43e-06	0.000143	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—psoriasis	2.4e-06	0.000141	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—psoriasis	2.38e-06	0.00014	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—psoriasis	2.23e-06	0.000131	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—psoriasis	2.21e-06	0.00013	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—psoriasis	2.14e-06	0.000126	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—psoriasis	2.13e-06	0.000126	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—psoriasis	2.11e-06	0.000124	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—psoriasis	2.04e-06	0.00012	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—psoriasis	1.96e-06	0.000116	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—psoriasis	1.95e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—psoriasis	1.87e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—psoriasis	1.85e-06	0.000109	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—psoriasis	1.83e-06	0.000108	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—psoriasis	1.81e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—psoriasis	1.7e-06	9.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—psoriasis	1.69e-06	9.92e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—psoriasis	1.66e-06	9.78e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—psoriasis	1.54e-06	9.08e-05	CbGpPWpGaD
